Stockscreener 앱 받기
6.81
1.95%
0.13
시간 외 거래:
6.82
0.01
+0.15%
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Nigeria
Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results - MarketBeat
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Nigeria
GYRE: Net loss widened to $32.8 million on $53.5 million revenue, with strong liquidity maintained - TradingView
Gyre Therapeutics (NASDAQ: GYRE) swings to 32,849 H1 2026 net loss - Stock Titan
Gyre Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gyre Therapeutics Q2 EPS misses estimate despite sales beat - scanx.trade
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Gyre Therapeutics Sees 2026 Rev $100.5M-$111.0M >GYRE - Moomoo
Gyre Therapeutics Reports Second Quarter 2026 - Moomoo
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
GYRE Q2 Revenue Falls To $29.1 Million As Net Loss Widens - Quiver Quantitative
GYRE: Q2 2026 revenue reached $29.1M, net loss widened, and Cullgen acquisition expanded the pipeline - TradingView
Gyre Therapeutics reports Q2 2026 revenue $29.1M, GAAP EPS $(0.12); full-year revenue guidance affirmed - TradingView
Gyre Therapeutics, Inc. Affirms Earnings Guidance for the Full Year of 2026 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: A 191% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
L9S.DU interactive stock chart | Gyre Therapeutics Inc. R stock - Yahoo Finance Australia
Gyre Therapeutics, Inc. (GYRE) grants director options on 40,000 shares - Stock Titan
Gyre Therapeutics (GYRE) director discloses no stock ownership - Stock Titan
Gyre Therapeutics (GYRE) awards director 40,000 stock options vesting to 2029 - Stock Titan
Weston Claire files initial ownership report at Gyre Therapeutics (GYRE) - Stock Titan
Gyre Therapeutics director Kirkby Maxwell files initial beneficial ownership statement - Bitget
GYRE THERAPEUTICS, INC. SEC Filing (Aug 4, 2026) - Stock Titan
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Gyr - The National Law Review
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Exploring a Promising 221% Upside in Biotech - DirectorsTalk Interviews
Gyre Therapeutics Inc (GYRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 5.8%Here's Why - MarketBeat
Gyre Therapeutics Inc (GYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gyre Therapeutics Inc (GYRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gyre Therapeutics Inc (GYRE) Balance Sheet - TradingKey
Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gyre Therapeutics Inc (GYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gyre Therapeutics Inc (GYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GYRE|Gyre Therapeutics Inc|Price:6.110|Chg%:+0.170 - TradingKey
Gyre Therapeutics Inc (GYRE) Income Statement - TradingKey
TradingKey - TradingKey
Cash flow from financing activities of Gyre Therapeutics Inc – GETTEX:L9S - TradingView
Gyre Therapeutics, Inc. Revenue Breakdown – NASDAQ:GYRE - TradingView
Gyre Therapeutics Inc (GYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Return on assets % of Gyre Therapeutics Inc – MUN:L9S - TradingView
Discontinued operations of Gyre Therapeutics Inc – MUN:L9S - TradingView
Return on assets % of Gyre Therapeutics Inc – GETTEX:A3EE5F - TradingView
Gyre Therapeutics Inc Statistics – MUN:L9S - TradingView
Gyre Therapeutics Inc Statistics – GETTEX:A3EE5F - TradingView
Gyre Therapeutics, Inc. (L9S.F) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Gyre Therapeutics Inc. (GYRE) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockReturn On Capital - dars.gov.et
Gyre Therapeutics Strengthens Board with New Director Appointments - The Globe and Mail
Gyre Therapeutics Appoints Three New Members to its Board of Directors - The Manila Times
Gyre Therapeutics appoints three directors to board By Investing.com - Investing.com Nigeria
Gyre Therapeutics appoints three directors to board - Investing.com
Gyre Therapeutics (Nasdaq: GYRE) adds three directors, expanding expertise - Stock Titan
Gyre Therapeutics, Inc. Announces Board and Committee Changes, Effective August 1, 2026 - marketscreener.com
Gyre Therapeutics Inc. (GYRE) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise in Pre-Revenue StageNew Analyst Coverage - dars.gov.et
Gyre Therapeutics (GYRE) Registration filing Summary - Quartr
Cullgen $300M all-stock deal expands Gyre Therapeutics (Nasdaq: GYRE) - Stock Titan
Yue Xiong Net Worth (2026) - GuruFocus
Jialiang (nmn) Wang Net Worth (2026) - GuruFocus
Joshua Benjamin Bergmann Net Worth (2026) - GuruFocus
Form S-3/A Gyre Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Gyre Therapeutics (Nasdaq: GYRE) details 31.3M-share resale and China risks - Stock Titan
Gyre Therapeutics Inc. (GYRE) Q1 2026 Earnings: Narrower Net Loss Beats Estimates as Operational Discipline ProgressesNet Income Trends - po-news-eg.net
1.80%
1.77%
자본화:
|
볼륨(24시간):